{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023419","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.822266+00:00","generated_at":"2026-05-16T19:55:43.186672+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M","bullets":["Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.","R&D expenses dropped to $0.5M in Q3 2025 from $2.4M in Q3 2024 as XYNGARI Phase 3 trial concluded.","Strategic pivot to OTC dermatology; first product is a once-weekly acne kit using Spongilla technology, launch mid-2026.","Company plans to sell OTC acne kit directly to consumers, estheticians, and dermatologists for in-office use."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023419","json":"https://secwatch.observer/filing/0001493152-25-023419.json","markdown":"https://secwatch.observer/filing/0001493152-25-023419.md","text":"https://secwatch.observer/filing/0001493152-25-023419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/0001493152-25-023419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:55:43.186672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}